(ELAN) Elanco Animal Health - Ratings and Ratios

Elanco Animal Health Incorporated (NYSE: ELAN) is a leading animal health company that develops, manufactures, and markets a wide range of products for both pets and farm animals. With a strong focus on innovation, the company provides solutions that prevent disease, promote health, and enhance productivity in the animal health sector.

The companys product portfolio is extensive, catering to both companion animals and livestock. For pets, Elanco offers parasiticides and vaccines under well-known brands like Seresto, Advantage, and Advocate, protecting against fleas, ticks, and worms. They also provide therapeutics for pain, osteoarthritis, and other health issues in pets through brands like Galliprant. In the livestock space, Elanco supplies vaccines, antibiotics, and nutritional health products for poultry, aquaculture, and ruminant and swine production, with brands such as Rumensin and Baytril.

Elanco distributes its products through a diverse network, including veterinarians, third-party distributors, and producers like beef and dairy farmers, as well as pork and poultry operations. This broad distribution network highlights the companys extensive reach and market penetration.

Founded in 1954 and headquartered in Greenfield, Indiana, Elanco has a long-standing history in the animal health industry, underscoring its experience and stability. With a market capitalization of over $5.7 billion, the company is a significant player in the pharmaceuticals sector. Its financial metrics, including a P/E ratio of 28.44 and a forward P/E of 12.27, suggest potential growth. The P/B ratio of 0.88 and P/S ratio of 1.29 provide further insight into its valuation relative to book value and revenue generation.

Elancos commitment to innovation and its comprehensive product range position it as a key player in the animal health market, making it a notable consideration for investors and fund managers assessing opportunities in this sector.